SCHEMBL29284151

SCHEMBL29284151

CN1CCN(CCOc2nnc(Cl)cc2N)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SIGMAR1 Q99720 3/20 0.41
KCNH2 Q12809 1/20 0.41
CXCR1 P25024 1/20 0.40
HTR4 Q13639 1/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LTA4H P09960 1/20 0.38
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
RIPK2 O43353 1/20 0.38
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
MCHR1 Q99705 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29284045 0.80 MEN1 (0.40) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL25131083 0.79 MEN1 (0.46) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL30226437 0.79 MEN1 (0.46) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL30226490 0.76 AIMP2 (0.42) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL31009131 0.76 MEN1 (0.36) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL29284057 0.74 TDP1 (0.42) ALDH1A1HTTSMN1; SMN2
SCHEMBL25131703 0.72 TDP1 (0.44) ALDH1A1LMNA
SCHEMBL17581307 0.72 RIPK2 (0.46) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL17581182 0.72 HSP90AB1 (0.46) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL25131711 0.72 TDP1 (0.47) MEN1KMT2AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011299-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-01-09 US disclosed
EP-4405343-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-07-31 EP disclosed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN disclosed
WO-2023046698-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011299-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 MEN1 3770/4885KMT2A 2453/4885KDM4E 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.